OPKO Health announced asset sales, advanced an EBV vaccine Phase 1 trial, and saw FDA approval for prostate cancer screening.
5 reports, 3 independent
Updated Sep 11
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
OPKO Health announced asset sales, advanced an EBV vaccine Phase 1 trial, and saw FDA approval for prostate cancer screening.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Discussion of potential EBV vaccine clinical updates and Nasdaq usage by OPKO Health.1 source
OPKO advances EBV vaccine trial and receives FDA approval for prostate cancer screening.1 source
Keep exploring
The entities involved
-
OPKO Health (Ireland)
company in Waterford, Ireland
Nothing else this week.
-
Merck
public company in Indonesia
- FDA
Related events
Coverage
Newest first; wire copies grouped- yahoo.com
- Insider MonkeyOPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics We recently published 12 Best Healthcare Stocks to Buy Under $30. OPKO Health, Inc. (NASDAQ:OPK) is one of the
- ZacksOPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates OPKO Health (OPK) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to